A cohort study among university students: Identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis

Clinical Infectious Diseases

Volumn 43, Issue 3, 2006, Pages 276-282

  Crawford, Dorothy H ^a   Macsween, Karen F ^a   Higgins, Craig D ^b   Thomas, Ranjit ^a   McAulay, Karen ^a   Williams, Hilary ^a   Harrison, Nadine ^a   Reid, Stuart ^a   Conacher, Margaret ^a   Douglas, Jill ^a   Swerdlow, Anthony J ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; B LYMPHOCYTE; COHORT ANALYSIS; CONDOM; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; INFECTIOUS MONONUCLEOSIS; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ORAL SEXUAL CONTACT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SEROCONVERSION; SEXUAL INTERCOURSE; SYMPTOMATOLOGY; T LYMPHOCYTE; UNIVERSITY STUDENT; VIRUS IMMUNITY; VIRUS LOAD; VIRUS TRANSMISSION; VIRUS TYPING;

ADULT; COHORT STUDIES; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; INFECTIOUS MONONUCLEOSIS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SEROLOGIC TESTS; STUDENTS; UNIVERSITIES;

EID: 33746035693     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/505400     Document Type: Article

References (36)

1. Niederman JC, McCollum RW, Henle G, Henle W. Infectious mononucleosis: clinical manifestations in relation to EB virus antibodies. JAMA 1968; 203:205-9.
2. + T cells in acute infectious mononucleosis. Nature Med 1996; 2:906-11.
3. Foss HD, Herbst H, Hummel M, et al. Patterns of cytokine gene expression in infectious mononucleosis. Blood 1994; 83:707-12.
4. Biglino A, Sinicco A, Forno B, et al. Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis. Clin Immunol Immunopathol 1996; 78:61-9.
5. Williams H, Macsween K, McAulay K, et al. Analysis of immune activation and clinical events in acute infectious mononucleosis. J Infect Dis 2004; 190:63-71.
6. Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 2001; 356:461-73.
7. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985; 35:35-42.
8. Sixbey JW, Lemon SM, Pagano JS. A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet 1986; 2:1122-4.
9. Israele V, Shirley P, Sixbey JW. Excretion of the Epstein-Barr virus from the genital tract of men. J Infect Dis 1991; 163:1341-3.
10. Näher H, Gissmann L, Freese UK, Petzoldt D, Helfrich S. Subclinical Epstein-Barr virus infection of both the male and female genital tract: indication for sexual transmission. J Invest Dermatol 1992; 98:791-3.
11. de-Thé G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from a Ugandan prospective study. Nature 1978; 274:756-61.
12. Henle W, Henle G. The virus as the etiologic agent of infectious mononucleosis. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus. New York: Springer-Verlag, 1979:279-320.
13. Niederman JC, Evans AS, Subrahmanyan L, McCollum RW. Prevalence, incidence and persistence of EB virus antibody in young adults. New Engl J Med 1970; 282:361-5.
14. Sawyer RN, Evans AS, Niederman JC, McCollum RW. Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. J Infect Dis 1971; 123:263-70.
15. Infectious mononucleosis and its relationship to EB virus antibody: a joint investigation by university health physicians and P.H.L.S. laboratories. Brit Med J 1971; 4:643-6.
16. Hallee TJ, Evans AS, Niederman JC, Brooks CM, Voegtly H. Infectious mononucleosis at the US Military Academy: a prospective study of a single class over four years. Yale J Biol Med 1974; 47:182-95.
17. Hoagland RJ. The transmission of infectious mononucleosis. Am J Med Sci 1955; 229:262-72.
18. Williams H, Macsween K, McAulay K, et al. Analysis of immune activation and clinical events in acute infectious mononucleosis. J Infect Dis 2004; 190:63-71.
19. Silins SL, Sherritt MA, Silleri JM, et al. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 2001; 98:3739-44.
20. Dambaugh T, Wang F, Hennessy K, Woodland E, Rickinson A, Kieff E. Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells. J Virol 1986; 59:453-62.
21. Sample J, Young L, Martin B, et al. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 1990; 64:4084-92.
22. Zimber U, Adldinger HK, Lenoir GM, et al. Geographical prevalence of two types of Epstein-Barr virus. Virology 1986; 154:56-66.
23. Sculley TB, Apolloni A, Hurren L, Moss DJ, Cooper DA. Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis 1990; 162:643-8.
24. Luxton JC, Williams I, Weller I, Crawford DH. Epstein-Barr virus infection of HIV-seropositive individuals is transiently suppressed by high-dose acyclovir treatment. AIDS 1993; 7:1337-43.
25. Falk KI, Zou J-Z, Lucht E, Linde A, Ernberg I. Direct identification by PCR of EBV types and variants in clinical samples. J Med Virol 1997; 51:355-63.
26. Rickinson AB, Young LS, Rowe M. Influence of Epstein-Barr virus nuclear antigen EBNA2 on the growth phenotype of virus-transformed B cells. J Virol 1987; 61:1310-7.
27. Gratama JW, Ernberg I. Molecular epidemiology of Epstein-Barr virus infection. Adv Cancer Res 1995; 67:197-255.
28. Denis M, Haumont H, Bollen A. Vaccination against Epstein-Barr virus (EBV): report of phase II studies using recombinant viral glycoprotein gp350 in healthy adults [abstract 14.01]. In: Program and abstracts of the 11th Biennial Conference of the International Association for Research on Epstein-Barr Virus and Associated Diseases (Regensburg, Germany). 2004:305.
29. Henle G, Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bact 1966; 91:1248-56.
30. Reedman BM, Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 1973; 11:499-520.
31. Brooks JM, Croom-Carter DSG, Leese AM, Tierney RJ, Habeshaw G, Rickinson AB. Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains. J Virol 2000; 74:1801-9.
32. Hughes K. Odds ratios in cross-sectional studies. Int J Epidemiol 1995; 24:463-4.
33. Clayton D, Hills M. Statistical models in epidemiology. Oxford, United Kingdom: Oxford University Press, 1993.
34. Crawford DH, Swerdlow AJ, Higgins C, et al. Sexual history and Epstein-Barr virus infection. J Infect Dis 2002; 186:731-6.
35. Haque T, Crawford DH. PCR amplification is more sensitive than tissue culture methods for Epstein-Barr virus detection in clinical material. J Gen Virol 1997; 78:3357-60.
36. Perry M, Whyte A. Immunology of the tonsils. Immunol Today 1998; 19:414-21.